ENO1 lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer

Drug Resistance Updates · Published 2026-05-07 · DOI 10.1016/j.drup.2026.101413

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.drup.2026.101413

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles